"About New York Cancer & Blood Specialists At New York Cancer & Blood Specialists (NYCBS), our mission is to provide patients with cancer and blood disorders world-class, patient-centered affordable care in their communities, close to family and friends. As one of the Nation's leading community cancer centers, we are committed to providing the highest quality care to patients. At NYCBS, we diagnose and treat every kind of cancer and offer patients state-of-the-art treatments, clinical trials, and comprehensive support services to treat the mind, body, and soul, not just the cancer. We understand that cancer treatment can be challenging and require regular physician visits for treatment and follow-up care."

During the past decade, New York Cancer and Blood Specialists conducted 27 clinical trials. In the 10-year time frame, 27 clinical trials started and 4 clinical trials were completed, i.e. on average, 14.8% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 4 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

Out of the total clinical trials conducted in "New York Cancer and Blood Specialists" #1 sponsor was "Gilead Sciences" with 3 trials, followed by "Odonate Therapeutics, Inc." with 3 trials sponsored, "Bayer" with 2 trials sponsored, "Calithera Biosciences, Inc" with 2 trials sponsored and "Daiichi Sankyo, Inc." with 2 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 25 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "New York Cancer and Blood Specialists" #1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Columbia University" with 1 trials as a collaborator, "Daiichi Sankyo Co., Ltd." with 1 trials as a collaborator and "Jacobi Medical Center" with 1 trials as a collaborator. Other collaborators include 3 different institutions and companies that were collaborators in the rest 13 trials.

According to Clinical.Site data, the most researched conditions in "New York Cancer and Blood Specialists" are "Breast Cancer" (4 trials), "Myelodysplastic Syndromes" (3 trials), "Prostate Cancer" (3 trials), "Lymphoma" (2 trials) and "Myeloproliferative Neoplasm" (2 trials). Many other conditions were trialed in "New York Cancer and Blood Specialists" in a lesser frequency.

Most popular intervention types in "New York Cancer and Blood Specialists" are "Drug" (26 trials), "Other" (5 trials), "Biological" (3 trials), "Behavioral" (1 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (7 trials), "Atezolizumab" (3 trials), "Carboplatin" (3 trials), "Docetaxel" (3 trials) and "Ipatasertib" (3 trials). Other intervention names were less common.

The vast majority of trials in "New York Cancer and Blood Specialists" are 28 trials for "All" genders and 6 trials for "Male" genders.

Currently, there are NaN active trials in "New York Cancer and Blood Specialists". undefined are not yet recruiting, 15 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in New York Cancer and Blood Specialists, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in New York Cancer and Blood Specialists, 3 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 11 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".